PTP Stock Overview
Operates as a clinical-stage radiopharmaceutical development company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Pentixapharm Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.78 |
| 52 Week High | €5.10 |
| 52 Week Low | €2.40 |
| Beta | 0 |
| 1 Month Change | -14.33% |
| 3 Month Change | -3.64% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -38.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| PTP | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 10.3% | 2.9% | 4.1% |
| 1Y | n/a | -14.6% | 8.4% |
Return vs Industry: Insufficient data to determine how PTP performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how PTP performed against the German Market.
Price Volatility
| PTP volatility | |
|---|---|
| PTP Average Weekly Movement | 9.9% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: PTP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PTP's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Dirk Pleimes | www.pentixapharm.com |
Pentixapharm Holding AG operates as a clinical-stage radiopharmaceutical development company. It focuses on developing CXCR4 ligand-based radiopharmaceutical approaches for diagnostic and therapeutic programs in various hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. The company’s clinical pipeline includes PentixaTher, an Yttrium-90-based therapeutic against non-Hodgkin lymphomas; and PentixaFor, a Gallium-68-based companion diagnostic.
Pentixapharm Holding AG Fundamentals Summary
| PTP fundamental statistics | |
|---|---|
| Market cap | €69.39m |
| Earnings (TTM) | -€13.97m |
| Revenue (TTM) | €16.58m |
4.2x
P/S Ratio-5.0x
P/E RatioIs PTP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTP income statement (TTM) | |
|---|---|
| Revenue | €16.58m |
| Cost of Revenue | €3.74m |
| Gross Profit | €12.85m |
| Other Expenses | €26.82m |
| Earnings | -€13.97m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.56 |
| Gross Margin | 77.47% |
| Net Profit Margin | -84.28% |
| Debt/Equity Ratio | 0% |
How did PTP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/19 11:55 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pentixapharm Holding AG is covered by 0 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.